newsfilter
← Latest News
GlobeNewswire·

Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

  • Hemab Therapeutics (NASDAQ: COAG) announced that its management team will present at the 2026 Jefferies Global Healthcare Conference.
  • The fireside chat is scheduled for Thursday, June 4, 2026, at 9:20 AM ET in New York, NY.
  • A live webcast of the event will be available for replay in the Investors section of Hemab's website.
  • Hemab is developing sutacimig (HMB-001), a bispecific antibody for the prophylactic treatment of Glanzmann thrombasthenia & Factor VII deficiency.
  • Hemab is developing HMB-002, a monovalent antibody for the prophylactic treatment of Von Willebrand Disease.
  • Media inquiries can be directed to Peg Rusconi at Deerfield, while investor inquiries should be sent to Mads Behrndt at Hemab Therapeutics.